Evidence map›Paper›PMID 39649884›Full record

ReviewAnnals of medicine and surgery (2012)2024

Cardioprotective strategies in the management of chemotherapy-induced cardiotoxicity: current approaches and future directions.

Zeineb Al-Hasnawi, Hawraa Mohammed Hasan, Jaafar Mohammed Abdul Azeez, Naam Kadhim, Aya Ahmed Shimal, Maryam Hussein Sadeq, Noor Al-Huda Ali Motashar Mahood, Abdulmelik A N Al-Qara Ghuli, Ahmed Safaa Hussein, Priyadarshi Prajjwal and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of medicine and surgery (2012), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Overview of Oncology: Drug-Induced Cardiac Toxicity.Medicina (Kaunas, Lithuania) · 2025
    Review
  5. Article
  6. Suspected Denosumab-Associated Acute Coronary Syndrome.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zeineb Al-HasnawiCollege of Medicine, University of Kufa, Najaf, Iraq.ORCID https://orcid.org/0009-0003-5457-3760
Hawraa Mohammed HasanAl Kadhimiyah Teaching Hospital, Baghdad, Iraq.
Jaafar Mohammed Abdul AzeezBabylon College of Medicine, University of Babylon, Babil, Iraq.
Naam KadhimCollege of Medicine, University of Baghdad, Baghdad, Iraq.ORCID https://orcid.org/0009-0004-0595-322X
Aya Ahmed ShimalCollege of Medicine, University of Baghdad, Baghdad, Iraq.
Maryam Hussein SadeqCollege of Medicine, University of Baghdad, Baghdad, Iraq.ORCID https://orcid.org/0009-0007-3292-9526
Noor Al-Huda Ali Motashar MahoodAl-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq.
Abdulmelik A N Al-Qara GhuliCollege of Medicine, University of Diyala, Diyala, Iraq.
Ahmed Safaa HusseinUlyanovsk State University, Ulyanovsk State Medical University, Ulyanovsk, Russia.
Priyadarshi PrajjwalBharati Vidyapeeth Deemed University, Pune, India.
Hritvik JainAll India Institute of Medical Sciences, Jodhpur, India.
Aman GoyalDepartment of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India.
Omniat AmirAlmanhal Academy for Science, Khartoum, Sudan.ORCID https://orcid.org/0000-0002-5021-263X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chemotherapy-induced cardiotoxicity (CIC) is a significant challenge in cancer treatment, leading to heart failure and myocardial infarction. With rising cancer survival rates, the long-term cardiovascular health of survivors has gained importance. While several cardioprotective medications have been studied to mitigate chemotherapy's harmful effects on the heart, more research is needed to confirm their effectiveness and optimal use. Methodology: This review synthesizes evidence on cardioprotective drugs in managing CIC. The authors conducted a comprehensive literature search of peer-reviewed articles, clinical trials, and meta-analyses published between January 2000 and May 2024. Studies were selected based on relevance, quality, and focus on mechanisms, efficacy, and clinical outcomes of cardioprotective agents such as beta-blockers, ACE inhibitors, ARBs, statins, and dexrazoxane. Results and discussion: Cardioprotective medications show potential in alleviating the impact of chemotherapy on heart function. Beta-blockers and ACE inhibitors effectively reduce heart failure incidence and improve cardiac outcomes. Statins, with their anti-inflammatory and antioxidative properties, and dexrazoxane, which reduces anthracycline-induced cardiotoxicity, also show promise. However, variability in study designs, patient groups, and chemotherapy treatments complicates the establishment of standardized treatment protocols. Conclusion: Cardioprotective drugs hold significant promise in managing CIC and improving cardiac outcomes for cancer patients. Current evidence supports the efficacy of beta-blockers, ACE inhibitors, statins, and dexrazoxane. Further research is needed to establish standardized protocols, evaluate long-term safety, and optimize treatment timing. Integrating cardioprotective strategies into oncological care can enhance the quality of life and prognosis for cancer survivors.

Indexed as

ACE inhibitorsbeta-blockerscancer treatmentcardioprotective drugschemotherapy-induced cardiotoxicitystatins

Identifiers

PMID39649884
PMCPMC11623821

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.